Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multipeptide Vaccination +/- IL-12 and Daclizumab in Metastatic Melanoma
NCT01307618Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Feb 2011
- Primary completion
- Jan 2015
- Modality
- Therapeutic Vaccines, Cytokines & Interferons, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of NA-17.A2, recombinant MAGE-3.1 antigen, mart-1 antigen, gp100:209-217, recombinant interleukin-12 in melanoma, sponsored by National Cancer Institute. Started Feb 2011; status: terminated.
02
Drugs
NA-17.A2recombinant MAGE-3.1 antigenmart-1 antigengp100:209-217recombinant interleukin-12
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01307618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01307618.